Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of rhTNFR-Fc in Acute Gout
NCT05925166Completed
- Start
- Sep 2020
- Primary completion
- Jul 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised, open-label trial of etanercept in gout (2 arms). Primary endpoints: Joint pain intensity in the most affected joint at 5 days and Acute gout recurrence time. Started Sep 2020; status: completed.
02
Drugs
etanercept
03
Conditions
gout
Beyond the preview
Go deeper on NCT05925166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05925166.